Goldman Sachs Upgrades PerkinElmer and Affy, Downgrades Thermo Fisher | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded PerkinElmer and Affymetrix but downgraded Thermo Fisher Scientific.

In a report outlining its outlook for 2012 in the broad medical technology space, analysts Isaac Ro and David Roman upgraded the investment firm's rating for PerkinElmer to Buy from Neutral, saying changes it has made in recent years has left it well positioned in the coming year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.